Cerus Corporation (CERS)
NASDAQ:CERS
Want to see CERS full AI Analyst Report?
CERS Stock Chart & Stats
$1.92
-$0.02(-1.22%)
At close: 4:00 PM EST
$1.92
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.15 - $3.15
Previous CloseN/A
Volume302.69K
Average Volume (3M)2.42M
Market Cap
$573.06M
Enterprise Value$584.46M
Total Cash (Recent Filing)$80.42M
Total Debt (Recent Filing)$97.36M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Jul 30, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding200,368,970
10 Day Avg. Volume2,357,306
30 Day Avg. Volume2,421,212
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue2.62
Enterprise Value/Gross Profit4.83
Enterprise Value/Ebitda491.14
Forecast
1Y Price Target
$4.50Price Target Upside134.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$251.40M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable Revenue ModelINTERCEPT's consumable-heavy business ties revenue to procedure volumes and creates recurring, repeat-purchase demand. That structural revenue stream offers durable visibility and customer stickiness as blood centers and hospitals must repurchase disposables for each treated unit.
Consistent Top-line Growth And Improving Profitability TrendsSustained product revenue growth, raised guidance, and multiple quarters of positive adjusted EBITDA signal improving operating leverage. Continued kit/IFC traction and disciplined expense control suggest structural progress toward GAAP profitability and stronger cash generation over the medium term.
Stronger Liquidity And Lower-cost Debt FacilityRefinancing extends maturities, reduces annual interest expense and adds a $45M revolver, improving financial flexibility. Deferred amortization and expanded working-capital capacity support growth investments and smooth near-term cash flow demands as commercialization scales.
Bears Say
Gross Margin Compression And Ongoing UnprofitabilityMargin pressure from inflation, shipping, tariffs and FX has compressed gross margins into the low‑fifties, limiting operating leverage. Persistent GAAP losses constrain retained earnings and returns on equity, reducing capacity to self‑fund expansion without external capital.
Regulatory And Timing Risk For Red Blood Cell OpportunityThe INTERCEPT RBC program is a meaningful upside but remains subject to regulatory review, audits and potential follow-ups. Delays or additional requirements could postpone commercialization and revenue scaling, leaving a sizable growth opportunity lumpy and timing‑uncertain.
Potential Dilution And Elevated Executive ProtectionsA materially expanded equity pool and enhanced severance/acceleration increase potential dilution and fixed compensation obligations. Over time larger equity grants can weigh on EPS and shareholder returns and may complicate capital allocation if used extensively for retention or M&A.
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.15 and its highest was $3.15 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $573.06M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 34 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Apr 30, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.03.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 200,368,970 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 33.99%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (134.38% Upside)
$4.50 (134.38% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $53.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.70%
12-Months-Change
Fundamentals
Return on Equity
-15.36%
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CERS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and operational positives: strong Q1 top-line performance (24% product revenue growth), raised full-year guidance, robust IFC/platelet momentum, continued positive adjusted EBITDA, disciplined operating expense control, and advancing regulatory/product milestones (illuminator PMA submission and RBC trial readout). Offsetting these positives are persistent margin headwinds (gross margin down to 52%), macro pressures (inflation, tariffs, FX), regional logistical risks (Middle East), working capital-driven cash use, and timing uncertainty around the red blood cell CE Mark and the lumpy nature of IFC rollout. On balance, the highlights—notably recurring revenue growth, improved profitability trends, and strengthened guidance—outweigh the lowlights, though management cautions about margin and timing risks.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(134.38% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
5.62% Insiders
12.91% Mutual Funds
36.41% Other Institutional Investors
26.28% Public Companies and
Individual Investors